DAIICHISANKYO PHARMA DEVELOPMENT (DS5565-A-E312)

An open-label extension study of DS-5565 for 52 weeks in pain associated with Fibromyalgia.

 

Your Name (required)

Your Email (required)

Subject

Your Message

Please insert the following text to probe you are not a robot
captcha